Sickle cell disease (SCD) patients on chronic transfusion develop transfusional iron overload - with patterns and management nuances distinct from thalassemia.
1. Why Chronic Transfusion in SCD? #
- Primary stroke prevention in children with abnormal transcranial Doppler (TCD) velocities
- Secondary stroke prevention after a clinical or silent infarct
- Recurrent acute chest syndrome uncontrolled by hydroxyurea
- Pulmonary hypertension, progressive sickle nephropathy
2. Distinct Iron Overload Pattern #
Compared with thalassemia, SCD iron overload often shows:
- More variable hepatic iron distribution
- Less cardiac iron loading at comparable ferritin levels (in some series)
- Higher baseline inflammation - ferritin elevated independent of iron stores
3. Monitoring Emphasis on LIC #
Because inflammation elevates ferritin in SCD, LIC by MRI is especially valuable for assessing true iron burden. Cardiac T2* may also be monitored in high-burden patients.
4. Deferasirox in SCD #
Deferasirox is approved for chronic transfusional iron overload in SCD. Starting dose is typically 20 mg/kg/day (dispersible formulation), titrated by LIC and ferritin trends with attention to tolerability.
5. Renal Considerations #
SCD patients often have baseline sickle nephropathy - careful creatinine monitoring before and during chelation is essential. Avoid concurrent nephrotoxins where possible.
6. Public-Health Perspective #
SCD is one of the most common monogenic disorders globally, with a particularly high prevalence in sub-Saharan Africa, parts of the Middle East, India and the Caribbean. Reliable supply of oral iron chelators across these regions is essential - DEFRATAJ is supplied widely. See SCD page.